[go: up one dir, main page]

WO2001060174A3 - Weight loss induced by reduction in neuropeptide y level - Google Patents

Weight loss induced by reduction in neuropeptide y level

Info

Publication number
WO2001060174A3
WO2001060174A3 PCT/US2001/005316 US0105316W WO0160174A3 WO 2001060174 A3 WO2001060174 A3 WO 2001060174A3 US 0105316 W US0105316 W US 0105316W WO 0160174 A3 WO0160174 A3 WO 0160174A3
Authority
WO
WIPO (PCT)
Prior art keywords
animal
animals
weight loss
compound
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/005316
Other languages
French (fr)
Other versions
WO2001060174A2 (en
Inventor
Thomas M Loftus
Craig A Townsend
Gabriele Ronnett
M Daniel Lane
Francis P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to JP2001559278A priority Critical patent/JP2003528051A/en
Priority to EP01910959A priority patent/EP1259121A2/en
Priority to US10/476,513 priority patent/US20040157918A1/en
Priority to AU2001238515A priority patent/AU2001238515A1/en
Priority to CA002400136A priority patent/CA2400136A1/en
Publication of WO2001060174A2 publication Critical patent/WO2001060174A2/en
Publication of WO2001060174A3 publication Critical patent/WO2001060174A3/en
Anticipated expiration legal-status Critical
Priority to US11/657,536 priority patent/US20070197638A1/en
Priority to US12/558,313 priority patent/US20100022639A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Steroid Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted α-methylene-β-carboxyl-η-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.
PCT/US2001/005316 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level Ceased WO2001060174A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001559278A JP2003528051A (en) 2000-02-16 2001-02-16 Weight loss induced by reduced neuropeptide Y levels
EP01910959A EP1259121A2 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
US10/476,513 US20040157918A1 (en) 2001-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
AU2001238515A AU2001238515A1 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
CA002400136A CA2400136A1 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level
US11/657,536 US20070197638A1 (en) 2000-02-16 2007-01-25 Weight loss induced by reduction in neuropeptide level
US12/558,313 US20100022639A1 (en) 2000-02-16 2009-09-11 Methods of Inducing Weight Loss

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18290100P 2000-02-16 2000-02-16
US60/182,901 2000-02-16
US20856000P 2000-06-02 2000-06-02
US60/208,560 2000-06-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/657,536 Continuation US20070197638A1 (en) 2000-02-16 2007-01-25 Weight loss induced by reduction in neuropeptide level

Publications (2)

Publication Number Publication Date
WO2001060174A2 WO2001060174A2 (en) 2001-08-23
WO2001060174A3 true WO2001060174A3 (en) 2002-04-25

Family

ID=26878528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005316 Ceased WO2001060174A2 (en) 2000-02-16 2001-02-16 Weight loss induced by reduction in neuropeptide y level

Country Status (6)

Country Link
EP (1) EP1259121A2 (en)
JP (1) JP2003528051A (en)
KR (1) KR20030016228A (en)
AU (1) AU2001238515A1 (en)
CA (1) CA2400136A1 (en)
WO (1) WO2001060174A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007556A (en) 2002-02-08 2005-12-05 Univ Johns Hopkins Med Stimulation of cpt-1 as a means to reduce weight.
MXPA05000152A (en) * 2002-07-01 2005-10-24 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same.
EP1548131A3 (en) * 2003-12-22 2005-07-27 F. Hoffmann-La Roche Ag Novel targets for obesity from skeletal muscle
AU2005222707B2 (en) * 2004-03-18 2010-06-17 Fasgen, Llc Control of feeding behavior by changing neuronal energy balance
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
JPH10287637A (en) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd Amidine derivative
EP0945440A1 (en) * 1996-12-16 1999-09-29 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
WO1999052363A1 (en) * 1998-04-15 1999-10-21 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
EP0945440A1 (en) * 1996-12-16 1999-09-29 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JPH10287637A (en) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd Amidine derivative
WO1999052363A1 (en) * 1998-04-15 1999-10-21 Nutriceutical Technology Corporation Method of regulating appetite and metabolism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199905, Derwent World Patents Index; Class B05, AN 1999-048775, XP002191407 *

Also Published As

Publication number Publication date
JP2003528051A (en) 2003-09-24
EP1259121A2 (en) 2002-11-27
AU2001238515A1 (en) 2001-08-27
CA2400136A1 (en) 2001-08-23
KR20030016228A (en) 2003-02-26
WO2001060174A2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
PL402389A1 (en) Method for inhibiting Raf kinase activity in humans or inanimals
MXPA04009765A (en) Method of improving absorption of vitamin e by a pet animal.
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
PT1406698E (en) Lipoxin analogs as novel inhibitors of angiogenesis
IL193771A (en) Compositions having cholesteryl ester transfer protein inhibitory activity
MY144232A (en) 5-substituted-2-phenylamino benzamides as mek inhibitors
HK1047036A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2005020973A3 (en) Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2008030752A3 (en) Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
IL162515A0 (en) Substituted diketopiperazines as oxytocin antagonists
WO2001060174A3 (en) Weight loss induced by reduction in neuropeptide y level
WO2002102978A3 (en) Human growth hormone antagonists
DE60101559T2 (en) USE OF COMT INHIBITORS AS ANALGETICS
MX2007005238A (en) A transmucosal veterinary composition comprising detomidine.
TW200616621A (en) Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
EP1050303A3 (en) Methods and compositions for treating age-related behavioral disorders in companion animals
EP1550443A4 (en) Composition against stress-related diseases
WO2004058137A3 (en) Compounds for oral dosage of active substances requiring a taste masking
WO2005035500A3 (en) Therapeutic agents useful for treating pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001238515

Country of ref document: AU

Ref document number: 2400136

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 559278

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020027010680

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001910959

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910959

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027010680

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10476513

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001910959

Country of ref document: EP